Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6114064 | 0.98 | ALDH1A1 (0.48) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| SCHEMBL10663971 | 0.84 | ALDH1A1 (0.45) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| SCHEMBL8738727 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| Bromide SCHEMBL6113873 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| SCHEMBL6121242 | 0.78 | ALDH1A1 (0.54) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| SCHEMBL4797009 | 0.78 | RXFP1 (0.45) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| SCHEMBL16434197 | 0.78 | ALDH1A1 (0.54) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| SCHEMBL6761935 | 0.78 | ALDH1A1 (0.55) | ALDH1A1KMT2AHPGDTSHRNPC1 | |
| SCHEMBL3067153 | 0.77 | ALDH1A1 (0.40) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| Hydrochloric Acid SCHEMBL8552956 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KMT2AHPGDTSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129842-A1 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| WO-2012068209-A2 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | WO | disclosed |
| US-20120129842-A1 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129842-A1 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP1, MMP9, MMP2 | ALDH1A1 648/4885MAPT 3531/4885KMT2A 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.